Immune Checkpoint Inhibitors in the Treatment of Stage III NSCLC: A Primer for Managed Care Pharmacy

Watch an on-demand Webcast and download slidesets from our live symposia at AMCP 2018 and AMCP Nexus 2018 where our pharmacy and oncology experts reviewed the rationale for checkpoint inhibitor therapy in unresectable stage III NSCLC how to optimally integrate checkpoint inhibitors into this setting and strategies for identifying and managing immune-related adverse events.

Share

Program Content

No activities added yet

No activities added yet

Supporters

This activity is supported by an educational grant from

AstraZeneca